Allogene Therapeutics Inc (ALLO)
2.09
+0.14
(+7.18%)
USD |
NASDAQ |
Dec 24, 16:00
Allogene Therapeutics Enterprise Value: 146.65M for Dec. 24, 2024
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals Inc | 1.635B |
| AIM ImmunoTech Inc | 7.953M |
| Perspective Therapeutics Inc | -46.50M |
| Protalix BioTherapeutics Inc | 103.66M |
| Armata Pharmaceuticals Inc | 164.08M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -66.29M |
| Total Expenses (Quarterly) | 61.05M |
| EPS Diluted (Quarterly) | -0.32 |
| Earnings Yield | -74.64% |
| Normalized Earnings Yield | -82.36 |